VLPNY vs PTGX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
VLPNY · VOESTALPINE AG UNSP ADR EACH REPR 1/5 ORD EUR0.00$9.00 ▼ 3.85%
PTGX · Protagonist Therapeutics$132.04 ▼ 2.38%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- VLPNY +31.7%
- PTGX +58.6%
Head to head
| Metric | VLPNY | PTGX |
|---|---|---|
| Price | $9.00 | $132.04 |
| Change today | ▼ 3.85% | ▼ 2.38% |
| Market cap | $8.55B | $8.54B |
| Return, 3 months | -13.9% | -12.0% |
| Return, year to date | +7.7% | +51.2% |
| Return, 1 year | +31.7% | +66.0% |
| P/E (TTM) | 13.0 | 27.9 |
| P/B | 0.9 | 7.9 |
| P/E percentile vs own 5y | – | 98th |
| Dividend yield | 1.91% | – |
| Revenue growth (YoY, latest qtr) | – | +3,749.2% |
| Net profit growth (YoY) | – | +568.3% |
| Gross margin | – | – |
| Operating margin | – | 20.7% |
| Net margin | – | 29.4% |
| Return on equity | – | 11.0% |
| Analyst target vs. price | – | +32.2% |
| Analyst buy share | – | 100% |
| RSI (14) | 33 | 39 |
| 30-day volatility | 32.9% | 37.8% |
| Max drawdown, 1 year | -28.2% | -18.8% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VLPNY is the largest of the group by market value.
- PTGX has returned the most over the past year.
- VLPNY carries the lowest trailing P/E.
- VLPNY has been the calmest stock over the last 30 days.